Franz von Nussbaum
Overview
Explore the profile of Franz von Nussbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Nussbaum F, Testolin G
J Med Chem
. 2025 Feb;
PMID: 39961794
Chymase is a serine protease that has been studied as a drug target in inflammatory diseases, so far with limited success. Fulacimstat is a novel drug candidate inhibiting chymase that...
2.
Graham K, Lienau P, Bader B, Prechtl S, Naujoks J, Lesche R, et al.
Cell Chem Biol
. 2024 Mar;
31(7):1247-1263.e16.
PMID: 38537632
This study describes the identification and target deconvolution of small molecule inhibitors of oncogenic Yes-associated protein (YAP1)/TAZ activity with potent anti-tumor activity in vivo. A high-throughput screen (HTS) of 3.8...
3.
Ali A, Bauser M, Bertrand S, Blackaby W, Boss C, Bossart M, et al.
ChemMedChem
. 2023 Jun;
18(13):e202300127.
PMID: 37276375
The status of industrial Medicinal Chemistry was discussed with European Medicinal Chemistry Leaders from large to mid-sized pharma and CRO companies as well as biotechs. The chemical modality space has...
4.
Diamanti E, Mendez M, Ross T, Kuttruff C, Lefranc J, Klingler F, et al.
ChemMedChem
. 2022 Oct;
17(21):e202200419.
PMID: 36198574
The Frontiers in Medicinal Chemistry (FiMC) meeting, which represents the largest international medicinal chemistry conference in Germany, took place from March 14 to 16 2022 in a fully virtual format....
5.
Wortmann L, Brauer N, Holton S, Irlbacher H, Weiske J, Lechner C, et al.
J Med Chem
. 2021 Oct;
64(21):15883-15911.
PMID: 34699202
PIP4K2A is an insufficiently studied type II lipid kinase that catalyzes the conversion of phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4,5-bisphosphate (PI4,5P). The involvement of PIP4K2A/B in cancer has been suggested, particularly...
6.
Lucking U, Kosemund D, Bohnke N, Lienau P, Siemeister G, Denner K, et al.
J Med Chem
. 2021 Jul;
64(15):11651-11674.
PMID: 34264057
Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development,...
7.
Lemos C, Schulze V, Baumgart S, Nevedomskaya E, Heinrich T, Lefranc J, et al.
Cell Oncol (Dordr)
. 2021 Jan;
44(3):581-594.
PMID: 33492659
Purpose: 5' adenosine monophosphate-activated kinase (AMPK) is an essential regulator of cellular energy homeostasis and has been associated with different pathologies, including cancer. Precisely defining the biological role of AMPK...
8.
Lucking U, Wortmann L, Wengner A, Lefranc J, Lienau P, Briem H, et al.
J Med Chem
. 2020 Jun;
63(13):7293-7325.
PMID: 32502336
The ATR kinase plays a key role in the DNA damage response by activating essential signaling pathways of DNA damage repair, especially in response to replication stress. Because DNA damage...
9.
Schulze V, Klar U, Kosemund D, Wengner A, Siemeister G, Stockigt D, et al.
J Med Chem
. 2020 Apr;
63(15):8025-8042.
PMID: 32338514
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of...
10.
Lefranc J, Schulze V, Hillig R, Briem H, Prinz F, Mengel A, et al.
J Med Chem
. 2019 Dec;
63(2):601-612.
PMID: 31859507
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKKε are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles...